BONE MORPHOGENETIC PROTEINS (BMPs) IN PERIODONTICS

Comprehensive Theory Examination Notes

---

1. INTRODUCTION AND HISTORICAL BACKGROUND

• The concept of bone morphogenesis was first introduced by Marshall R. Urist, who made the key discovery that demineralized, lyophilized segments of bone induced new bone formation when implanted in muscle pouches in rabbits. This discovery was published in 1965 in Science.
• The term "bone morphogenetic protein" (BMP) first appeared in the scientific literature via the Journal of Dental Research in 1971.
• Bone morphogenetic (or morphogenic) proteins are now referred to as BMPs for convenience.
• Hari Reddi unraveled the sequence of events involved in bone matrix-induced bone morphogenesis. On the basis of this work, it seemed likely that "morphogens" were present in the bone matrix. A systematic study using a battery of bioassays for bone formation was undertaken to isolate and purify putative bone morphogenetic proteins.
• Wozney et al. succeeded in cloning the genes that code for BMPs in 1988. Thereafter, BMP family members were identified by Wang and Reddi, leading to the discovery of several growth factors.

Source: Misch Implantology 4th Edition; Bone Augmentation in Oral Implantology (Khoury & Antoun)

---

2. DEFINITION AND NATURE

• Bone morphogenic proteins (BMPs) comprise a group of regulatory glycoproteins that are members of the transforming growth factor-beta (TGF-β) superfamily that function as differentiation factors.
• These proteins induce cellular differentiation of stem cells into chondroblastic and osteogenic cells.
• BMPs are multifunctional polypeptides belonging to the TGF-β superfamily of proteins.
• BMPs are not only powerful regulators of cartilage and bone formation during embryonic development and regeneration in postnatal life, but also participate in the development and repair of other organs such as the brain, kidney, and nerves (Reddi 2001).
• The human genome encodes at least 20 BMPs (Reddi 1998). To date, 20 BMPs have been identified.
• BMPs are abundant in bone and are produced by many cell types and osteoblasts in particular.
• The most remarkable feature of BMPs is their ability to induce ectopic bone formation (Urist 1965).

Source: Newman & Carranza's 14th Ed., Clinical Periodontology and Implant Dentistry 6th Ed. (Lang & Lindhe), Periodontics Medicine Surgery Implants (Rose et al.), Bone Augmentation in Oral Implantology (Khoury & Antoun)

---

3. CLASSIFICATION / TYPES OF BMPs

• BMP-2 is the primary osteoinductive protein of the BMP family.
• In the field of periodontal regeneration, much of the research interest has focused on BMP-2 (OP-2), BMP-3 (osteogenin), and BMP-7 (OP-1).

Source: Bone Augmentation in Oral Implantology (Khoury & Antoun); Periodontics Medicine Surgery Implants (Rose et al.); Newman & Carranza's 14th Ed.

---

4. MECHANISM OF ACTION

4A. Signaling Pathways

• Several pathways that influence osteoblastogenesis and bone formation are involved, including the Smad pathway, Hedgehog pathway, TGF-β pathway, and cytokine-cytokine receptor interaction.
• BMPs bind to type I and II receptors that function as serine-threonine kinases.
• The type I receptor protein kinase phosphorylates intracellular signaling substrates called Smads (Sma gene in Caenorhabditis elegans and Mad gene in Drosophila).
• The phosphorylated BMP-signaling Smads enter the nucleus and initiate the production of other bone-related matrix proteins, leading to bone morphogenesis.

Source: Clinical Periodontology and Implant Dentistry 6th Ed. (Lang & Lindhe); Newman & Carranza's 14th Ed.

4B. BMP-2 Specific Mechanism

• BMP-2 target genes include a wide cohort of transcription factors located in the cell nucleus.
• The osteogenic effects of BMP-2 are mediated by the formation of Runx2-Smad complexes.
• BMP-2 promotes osteoblast maturation by increasing the expression of a series of transcription factors in the cell nucleus (RUNX2, OSX, DLX5), which lead to the expression of OSE2, the osteoblast marker gene that is responsible for osteoblast differentiation.
• Osteoprotegerin is secreted by osteoblasts in response to vitamin D and BMP-2, thereby blocking osteoclast formation.

Source: Newman & Carranza's 14th Ed.; Essentials of Clinical Periodontology and Periodontics

4C. Sequential Cascade of Bone Induction

BMP stimulus
        |
        v
CHEMOTAXIS
(Movement of motile cells toward increasing BMP concentration gradient)
        |
        v
MITOSIS
(Cell division -- daughter cells have same chromosomes as parent nucleus)
        |
        v
DIFFERENTIATION
(Cells specialize to become bone cells / osteoblasts)
        |
        v
PRODUCTION OF OSTEOID
(New immature bone material)
        |
        v
REMODELING
(Lamellar, mature bone formation)

Source: Misch Implantology 4th Edition

4D. Role in DFDBA Osteoinduction

• BMPs promote recruitment of mesenchymal cells, chondroblast differentiation, cartilage formation, vascular invasion, and finally, bone formation.
• When crude BMP preparations were placed in muscle or subdermal pouches:
  • Ectopic focal formation of cartilage was present after 12 days
  • Bone was present after 28 days
• This induction of mesenchymal stem cell differentiation to recapitulate endochondral bone formation stimulated clinical interest.

Source: Periodontics Medicine Surgery Implants (Rose et al.); Bone Augmentation in Oral Implantology (Khoury & Antoun)

---

5. ROLE OF BMPs IN OSTEOINDUCTION

• Osteoinduction is a process by which graft material is capable of promoting cementogenesis, osteogenesis, and new periodontal ligament. It is a chemical process by which molecules contained in the graft (BMPs) convert the neighboring cells into osteoblasts, which in turn form bone.
• Demineralization in cold, diluted hydrochloric acid exposes the components of bone matrix, which are closely associated with collagen fibrils and have been termed bone morphogenetic proteins (BMPs) (Carranza's 10th Ed., ref. 194).
• DFDBA is thought to have osteoinductive effects because it retains some of the original BMPs within the donor tissue matrix.
• However, more recent reports have suggested that bone augmentation with DFDBA is not osteoinductive because it does not contain the BMPs necessary to induce bone formation (Carranza's 10th Ed.).
• The most widely studied mediators of osteoinduction are the family of bone morphogenic proteins (BMPs).

Source: Carranza's 10th Ed.; Essentials of Clinical Periodontology and Periodontics; Bone Augmentation in Oral Implantology (Khoury & Antoun)

---

6. BMP CONTENT IN BONE GRAFTS

6A. Natural Concentration

• Human bone contains 1 μg/kg BMP and osseous proteins, combined with non-collagenous matrix (non-collagenous protein, NCP). Thus, 1 mg of BMP/NCP leads to the formation of visible newly formed bone deposits. (Khoury & Antoun)
• Approximately 10 kg of bovine bone yields 2 μg of BMP (Periodontics Medicine Surgery Implants)
• Another source states: 0.1 mg BMP/kg bone (Bone Augmentation in Oral Implantology)
• The isolation of BMPs requires 5 to 20 kg of bone to obtain sufficient protein for purification testing. (Bone and Soft Tissue Augmentation in Implantology)
• BMPs are present in FDBA and DFDBA, but the levels are so low that bovine bone yields only 2 μg of BMP. It is only through recombinant DNA technology (rhBMP) that BMP has been made available for clinical use.

Source: Newman & Carranza's 14th Ed.; Periodontics Medicine Surgery Implants (Rose et al.); Bone Augmentation in Oral Implantology (Khoury & Antoun); Bone and Soft Tissue Augmentation in Implantology

6B. BMP in DFDBA - Variability and Controversy

• Demineralization of FDBA will make BMP accessible for osteoinduction (Urist's studies).
• Becker et al. implanted human BMP preparations and DFDBA from four commercial bone banks into muscle pouches of athymic mice. Histologically, commercial DFDBA induced minimal amounts of new appositional bone (7.5-21.6%). However, Urist's partially purified human BMP preparations resulted in 96% of the field filled with new appositional bone.
• The discrepancy may be because of the modification of the bone-processing protocol used by the bone bank to minimize risk for infection.
• Denaturation of BMPs may occur during large batch processing of commercially available DFDBA.
• Shigeyama et al. showed that both preparations contained BMP-2, -4, and -7, but the laboratory-prepared DFDBA had greater concentrations of BMP-2, the primary osteoinductive protein of the BMP family.
• Young donor bone results in significantly greater quantities of BMPs retained in the bone allograft matrix compared with older donor bone.

Source: Periodontics Medicine Surgery Implants (Rose et al.); Carranza's 10th Ed.

---

7. RECOMBINANT HUMAN BMPs (rhBMPs)

7A. Production

• The recombinant DNA process encodes for the desired protein. Gene isolation is carried out by identification of the mRNA replicated during protein synthesis. Once the mRNA is isolated, it can be transcribed into DNA by reverse transcriptase enzyme. Complementary DNA is used by the cellular system for protein production.
• This process allows the accurate transcription of non-contaminated protein with real properties and in unlimited supply.
• Today, recombinant BMPs (rhBMPs) can be produced safely in the laboratory with cell cultures and are available as a mono-substance.

Source: Bone Augmentation in Oral Implantology (Khoury & Antoun)

7B. Available Forms

• rhBMP-2 and rhBMP-7 are the most frequently used in experimental and clinical studies, with good results.
• rhBMP-2 is U.S. FDA approved for some dental use.
• Laboratory-produced recombinant human BMPs (rhBMPs) are used in orthopedic applications (rhBMP-2 and rhBMP-7), such as spinal fusions and nonunions.
• rhBMP-2 (INFUSE) soaked onto an absorbable collagen sponge assists with ridge and sinus augmentation - FDA approved.

Source: Misch Implantology 4th Ed.; Newman & Carranza's 14th Ed.

---

8. CLINICAL APPLICATIONS OF BMPs IN PERIODONTICS

8A. Periodontal Regeneration

• BMPs belong to the category of "Miscellaneous Biologics Used for Periodontal Regeneration" (Newman & Carranza's 14th Ed., Chapter 63).
• BMPs are classified as "Biologic and biomimicry mediators" - as "growth differentiation factors to enhance periodontal regeneration" (Periodontics Medicine Surgery Implants).
• The locally applied HMTs (host modulatory therapies) currently approved by the FDA for adjunctive use during surgery are:
  1. Enamel matrix proteins (Emdogain)
  2. Recombinant human platelet-derived growth factor-BB (GEM 21S)
  3. BMP-2 (INFUSE) - for ridge and sinus augmentation
• Other biologics such as rhBMP and rhFGF have undergone clinical trials but have NOT been FDA approved for clinical use in periodontal regeneration specifically.

Source: Newman & Carranza's 14th Ed.

8B. Studies on BMP-2 in Periodontal Defects

• Early studies using crude preparations of BMP-2 and BMP-3 applied in surgically induced furcation defects appeared to stimulate periodontal regeneration.
• More recent studies with rhBMP-2 indicate that periodontal regeneration was associated with areas of ankylosis.
• When rhBMP-2 was used in horizontal periodontal bony defects, the gains in bone and cementum were 3.5 and 1.6 mm, respectively, compared with 0.8 and 0.4 mm for controls. Histologic analysis revealed periodontal regeneration with areas of ankylosis.
• Healing through ankylosis has been a concern; therefore, most of the research using rhBMPs has involved correction of intrabony, supra-alveolar, furcation, and fenestration defects, as well as implant site preparation.

Source: Newman & Carranza's 14th Ed.; Periodontics Medicine Surgery Implants (Rose et al.)

8C. BMP-7 (OP-1) in Periodontal Studies

• Contrary to BMP-2 findings, BMP-7 augmentation resulted in a significant increase in periodontal regeneration without any ankylosis.
• BMP-7, also known as osteogenic protein 1 (OP-1), stimulates bone regeneration around teeth, endosseous dental implants, and in maxillary sinus floor augmentation procedures (Giannobile et al. 1998; van den Bergh et al. 2000).
• More recently, BMP-7 has been utilized in an animal model to improve bone formation by incorporating BMP-7 into a patterned scaffold for the formation of PDL-like tissue and the overall integrity of the bone-PDL interface. Future translational and human studies are still needed.

Source: Periodontics Medicine Surgery Implants (Rose et al.); Clinical Periodontology and Implant Dentistry 6th Ed.; Newman & Carranza's 14th Ed.

8D. BMP-3 (Osteogenin) in Periodontal Defects

• A bone-inductive protein isolated from the extracellular matrix of human bones, termed osteogenin or BMP-3, has been tested in human periodontal defects and seems to enhance osseous regeneration.

Source: Carranza's 10th Ed.; Newman & Carranza's 14th Ed.

8E. BMP-12 in Periodontal Studies

• Investigations in animal models have shown the potential repair of alveolar bony defects using rhBMP-12 (Wikesjo et al. 2004) or rhBMP-2.

Source: Clinical Periodontology and Implant Dentistry 6th Ed. (Lang & Lindhe)

---

9. ROLE OF BMPs IN TOOTH DEVELOPMENT AND PERIODONTAL REPAIR

• Studies have demonstrated the expression of BMPs during tooth development and periodontal repair, including alveolar bone (Aberg et al. 1997; Amar et al. 1997).
• BMP4 expression is noted during tooth development; BMP4, BMP7, Wnt10b, and VEGF levels are increased during the healing process.
• BMPs are already present in native bone. According to the body's natural reparation process, after the death of the bone cells, an additional expression of BMP occurs for the regeneration.

Source: Clinical Periodontology and Implant Dentistry 6th Ed. (Lang & Lindhe); Bone and Soft Tissue Augmentation in Implantology

---

10. BMPs IN IMPLANT SITE PREPARATION AND BONE AUGMENTATION

10A. Implant Applications

• Four growth factors have potential use in implantology: BMP-2 and BMP-7, fibroblast growth factor (FGF-2), and platelet-derived growth factor (PDGF-B).
• BMP-2 is often used in bone-implant interaction studies because it seems to possess the highest osteoinductive potential among the BMPs.
• BMPs may be applied to bone sites through various delivery systems such as an absorbable collagen sponge used to augment the bone ridge before implant placement or implants with porous structures coated with rhBMP-2.
• Implants coated with CaP and BMPs showed statistically improved results in several studies.
• Statins induce the expression of BMP-2 mRNA that promotes bone formation. Simvastatin increases bone formation and concurrently suppresses osteoclast activity.

Source: Misch Implantology 4th Ed.

10B. rhBMP-2/ACS in Sinus Augmentation and Ridge Preservation

• rhBMP-2 (INFUSE) soaked onto an absorbable collagen sponge to assist with ridge and sinus augmentation - FDA approved.
• Fiorellini et al. (2005) reported that in a human buccal wall defect model, bone formation following tooth extraction was significant when the defect was treated with rhBMP-2 delivered by a bioabsorbable collagen sponge, compared to treatment with the collagen sponge alone.
• In a clinical trial, rhBMP-2 delivered by a bioresorbable collagen sponge revealed significant bone formation in a human maxillary sinus (Fiorellini et al. 2005).
• Fiorellini et al. conducted controlled studies with the use of rhBMP-2 (bone morphogenic protein) with acellular collagen sponge in extraction sites. They concluded the use of BMP induced significant bone formation for the future placement of dental implants. Histologically, the bone was similar to native bone and was load bearing.
• Rh-BMP is commercially available as an osteoinductive alloplastic bone graft material (Infuse Bone Graft, Medtronic Spinal and Biologics, Memphis, TN, USA).

Source: Misch Implantology 4th Ed.; Clinical Periodontology and Implant Dentistry 6th Ed.; Newman & Carranza's 14th Ed.

10C. rhBMP-2 in Critical-Sized Defects

• Studies have reported substantial preclinical data for rapid new bone formation using rhBMP-2 in critical-sized defects.
• The potential advantage of combining barrier membranes and rhBMP-2 for osteogenesis is evident.
• The inductive capacity of rhBMP-2 was demonstrated by impregnating a polymer carrier and placing the substrate in critical-sized rat mandibular defects with or without a barrier membrane. The study showed bony union of the defects for BMP-treated sites.

Source: Carranza's 10th Ed.

10D. Peri-implantitis Defects

• rhBMP-2 has been evaluated for bone formation and reosseointegration in peri-implantitis defects following surgical implantation (Hanisch et al. 1997).

Source: Newman & Carranza's 14th Ed. (reference list)

---

11. DELIVERY SYSTEMS / CARRIERS FOR BMPs

• The osteoinductive effect is obtained in vivo only when highly soluble BMPs are carried by a transporter.
• The use of a vector allows a reduction in the quantity needed and slow release systems can be obtained, despite rapid diffusion.
• Vectors should be biodegradable, non-immunogenic, amenable to remodeling, and adaptable to the bony contours that need regeneration. They can be organic or inorganic biomaterials.

Source: Bone Augmentation in Oral Implantology (Khoury & Antoun); Newman & Carranza's 14th Ed.; Bone and Soft Tissue Augmentation in Implantology

---

12. BMPs IN TISSUE ENGINEERING CONCEPT

• Tissue engineering is the manipulation of one or more of the three elements: signaling molecules (e.g., PDGF, BMP), scaffolds (e.g., CaPO4, collagen), or cells (e.g., osteoblasts, fibroblasts).

SIGNALING MOLECULES (e.g., BMP, PDGF)
              +
SCAFFOLDS (e.g., CaPO4, collagen)          -----> REGENERATION OF TISSUE/ORGANS
              +
CELLS (e.g., osteoblasts, fibroblasts)
              |
           TIME

• Extensive reconstructions are becoming more predictable, as demonstrated by the regeneration of a mandible formed in a patient by using a metal and polymer scaffold seeded with stem cells and BMPs (Warnke et al. 2004).
• IGF and BMPs are secreted by osteoblasts inside the osteoid matrix and control the transformation of immature to mature bone. These proteins are secreted during osteoclastic resorption of remodeled bone, promoting the proliferation of stem cells and preosteoblasts and their differentiation.

Source: Newman & Carranza's 14th Ed.; Clinical Periodontology and Implant Dentistry 6th Ed.; Bone Augmentation in Oral Implantology (Khoury & Antoun)

---

13. ADVERSE EFFECTS AND COMPLICATIONS

• Adverse events associated with the administration of BMPs have been reported, including:
  1. Osteolysis
  2. Seroma/hematoma
  3. Infection
  4. Arachnoiditis
  5. Dysphagia
  6. Increased neurological deficits
  7. Cancer

• High doses of BMP-2 have been associated with localized and temporary bone impairment or increased bone resorption caused by stimulation of osteoclast formation. However, once the levels drop, normal bone formation is observed.
• Use in Europe for dental implants is not permitted due to the many possible complications and adverse effects such as:
  1. Ectopic mineralization
  2. Severe pain, swelling, and hematoma
  3. Osteoclast-mediated bone loss
  4. Adipogenesis
  5. Neuralgia
  6. Unclear tumor genesis
• The very high cost of these materials also makes them unrealistic for use in dental implantology. In summary, the use of BMPs to improve bone regeneration in routine treatment is still not an option today (in Europe).
• rhBMPs and BMPs are costly, have a high dose requirement (several micrograms up to milligrams), and have a poor distribution profile.

Source: Newman & Carranza's 14th Ed.; Bone and Soft Tissue Augmentation in Implantology; Misch Implantology 4th Ed.

---

14. SUMMARY TABLE: BMPs IN PERIODONTICS - COMPARISON ACROSS REFERENCES

---

15. IN VITRO EFFECTS OF BMPs ON PERIODONTAL CELLS

• BMPs are synergistic with IGF-I in the differentiation and proliferation of osteoblasts. (Bone Augmentation in Oral Implantology)
• A study by Shigeyama et al. showed that DFDBA protein extracts containing BMP-2, -4, and -7 enhanced cell attachment. No extracts were effective in cell recruitment and chemotaxis.
• Increased immunostaining for BMP-2, BMP-7, TGF-β, and PDGF-BB was observed when an experimental sheep femoral defect was filled with calcium sulfate (relevant to carrier studies).

Source: Periodontics Medicine Surgery Implants (Rose et al.); Newman & Carranza's 14th Ed.

---

16. ROLE OF BMPs IN HOST MODULATION

• BMPs (specifically BMP-2, BMP-7) are classified as "Growth differentiation factors" under the category of local host modulatory therapies (HMTs).
• In the context of host modulation:
  • Platelet-derived growth factor (PDGF) - proliferative factor
  • Insulin-derived growth factor (IGF) - proliferative factor
  • Bone morphogenetic proteins (BMP-2, BMP-7) - growth differentiation factors

Source: Essentials of Clinical Periodontology and Periodontics

---

17. GENE THERAPY AND BMPs

• Major limitations associated with the use of growth and differentiation factors include their short biological half-lives. The factors, once applied, are subject to proteolytic breakdown and receptor binding problems and are dependent on the stability of the carrier system.
• Gene therapy can be used for extended local delivery of BMPs.
• In vivo osteogenic activity of an adenovirus expressing BMP7 has been studied in gene therapy approaches.
• BMP-7-transduced human fibroblasts form bone in vivo (gene therapy-directed osteogenesis).

Source: Periodontics Medicine Surgery Implants (Rose et al.); Clinical Periodontology and Implant Dentistry 6th Ed. (Lang & Lindhe)

---

18. RECENT TERMINOLOGY CHANGES / IMPORTANT NOTES

---

19. COMPREHENSIVE SUMMARY FLOWCHART: BMPs IN PERIODONTICS

BONE MORPHOGENETIC PROTEINS (BMPs)
              |
    __________|__________
    |                    |
 SOURCE               PRODUCTION
 (Bone matrix;         (Natural: low concentration
  all tissues)          2 μg/10 kg bovine bone)
                        (Recombinant: rhBMP via
                         recombinant DNA technology)
              |
    __________|__________
    |                    |
MECHANISM            CLASSIFICATION
(TGF-β superfamily)   (BMP-1 to BMP-20+;
(Binds Type I/II       Key: BMP-2, BMP-3,
 receptors)            BMP-7)
(Smad signaling)
(Runx2-Smad for BMP-2)
              |
    __________|__________
    |                    |
PERIO APPLICATIONS    IMPLANT APPLICATIONS
  |                       |
  |-- Furcation defects    |-- Ridge augmentation
  |   (crude BMP-2/3)      |-- Sinus augmentation
  |-- Intrabony defects    |-- Critical-sized defects
  |   (rhBMP-2 - ankylosis)|-- Post-extraction sockets
  |-- BMP-7 (no ankylosis) |-- Peri-implantitis
  |-- Supra-alveolar       |-- Implant surface coating
  |-- Fenestration defects
              |
    __________|__________
    |                    |
CARRIER SYSTEMS       COMPLICATIONS
(ACS - FDA approved)   (Osteolysis, ankylosis,
(Collagen sponge)       seroma, ectopic bone,
(Calcium sulfate)       cancer risk, costly)
(Polymers)
(Titanium mesh)
              |
         FUTURE
    (Gene therapy,
     Scaffold + BMP-7,
     PDL regeneration)

---

20. IMPORTANT EXAMINER KEYWORDS SUMMARY

---

REFERENCES (Source Documents Used)

1. Newman and Carranza's Clinical Periodontology and Implantology, 14th Edition - Chapter 63 (Periodontal Regeneration) and Chapter on Host Modulation
2. Carranza's Clinical Periodontology, 10th Edition - Chapter 67 (Bone Grafts) and Chapter 78 (Bone Augmentation)
3. Clinical Periodontology and Implant Dentistry, 6th Edition (Lang & Lindhe) - Chapter on Tissue Regeneration and Ridge Augmentation
4. Periodontics: Medicine, Surgery, and Implants (Rose, Mealey, Genco, Cohen) - Chapter 25 (Periodontal Regeneration)
5. Essentials of Clinical Periodontology and Periodontics - Host Modulation and Bone Loss chapters
6. Misch Implantology, 4th Edition - Bone Substitutes and Membranes, Implant Surface chapter
7. Bone Augmentation in Oral Implantology (Khoury & Antoun) - Chapter 14 (Growth Factors and BMPs)
8. Bone and Soft Tissue Augmentation in Implantology - Chapter on Biology of Bone Regeneration

---

---

What These Notes Cover (20 Sections)

1. Historical Background - Urist 1965, Hari Reddi, Wozney 1988 - all with exact source attributions
2. Definition and Nature - regulatory glycoproteins, TGF-β superfamily, differentiation factors
3. Classification Table - BMP-1 through BMP-9 with principal characteristics (from Khoury & Antoun)
4. Mechanism of Action - Smad signaling, Runx2-Smad complexes, RUNX2/OSX/DLX5/OSE2 pathway; Bone induction cascade flowchart
5. Osteoinduction Role - chemical mechanism, demineralization of DFDBA
6. BMP Content in Bone Grafts - exact concentrations from different references, DFDBA variability debate
7. Recombinant BMPs (rhBMPs) - production via recombinant DNA, available forms
8. Clinical Applications - periodontal defects (intrabony, furcation, supra-alveolar, fenestration), ankylosis concern with BMP-2 vs. no ankylosis with BMP-7
9. Tooth Development and Periodontal Repair - BMP expression during development
10. Implant Applications - ridge/sinus augmentation, INFUSE, post-extraction sockets, peri-implantitis
11. Delivery Systems Table - ACS, collagen, calcium sulfate, polymers, scaffolds
12. Tissue Engineering - three-element concept flowchart
13. Adverse Effects - full list from both perspectives (spine/systemic and dental-specific European perspective)
14. Cross-Reference Comparison Table - viewpoints from all 8 sources side-by-side
15. In Vitro Effects on periodontal cells
16. Host Modulation context
17. Gene Therapy and BMP delivery
18. Terminology Changes Table - osteogenin/BMP-3, OP-1/BMP-7, OP-2/BMP-2, INFUSE
19. Master Summary Flowchart
20. Examiner Keywords Table with clinical context